CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 38 enrolled
Drug / intervention
TRK-950 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02990481
NCT02990481Phase 1Completed
CompareCT.gov

A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid Tumors

Toray Industries, Inc·interventional·Posted Dec 13, 2016·Updated Apr 16, 2025

In Brief

A Phase 1 clinical trial evaluating TRK-950 for Locally Advanced or Metastatic Solid Carcinomas and 2 related conditions. Completed, enrolled 38 participants across 3 sites in 2 countries.

Detailed Summary

1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
CountriesFrance, United States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 13, 2016
Enrollment StartMar 6, 2017
Primary CompletionSep 16, 2019
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.6 years ago

Interventions

TRK-950biological

Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle

TRK-950biological

Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle

TRK-950biological

Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle